Chronic NEP inhibition for 2 weeks in heart failure rats improved cardiac function, reduced ventricular mass, and paradoxically lowered natriuretic peptide levels despite initially boosting them — suggesting sustained benefit.
Paradox explainedBNP went DOWN during NEP inhibition because the heart improved so much it released less BNP — treatment success, not drug failure
What the researchers found
Long-term NEP inhibition (2 weeks) in heart failure rats improved cardiac function, reduced ventricular remodeling, and paradoxically lowered ANP/BNP — the decrease reflecting improved cardiac status rather than drug failure.
Why it matters
The paradoxical BNP decrease during NEP inhibition initially confused clinicians. This study explains it: successful treatment reduces cardiac stress, which lowers BNP even though the drug prevents BNP breakdown.
How the study worked
Animal study in rats with experimental heart failure. Chronic NEP inhibitor treatment for 2 weeks. Cardiac function (echocardiography), ventricular mass, and plasma ANP/BNP measured.
What this study cannot tell us
Rat heart failure model. 2-week treatment is relatively short. The paradoxical peptide response may differ by heart failure severity.
How to read the evidence
Moderate evidence from a chronic animal treatment study with functional cardiac endpoints and biomarker measurements.
When this study was published
Published in 2001. This paradox is now recognized clinically — NT-proBNP (not affected by NEP) is recommended for monitoring patients on sacubitril/valsartan.
The bigger picture
This explains a clinical puzzle with sacubitril/valsartan (Entresto): BNP can decrease during treatment despite NEP inhibition supposedly boosting it. The cardiac improvement outweighs the enzyme inhibition effect.
Questions still open
- How should clinicians interpret BNP changes during Entresto therapy?
- Does the NP decrease indicate treatment success or confound monitoring?
- Should NT-proBNP (not affected by NEP) be used instead for monitoring during NEP inhibition?
Common questions
Why would a drug that boosts BNP actually lower BNP levels?
How should doctors monitor patients on Entresto?
Read the original research
Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
Cardiovascular research, 51(3), 608-17
Citation
Maki, T; Nasa, Y; Yamaguchi, F; Yoshida, H; Mori, M; Takada, T; Horikawa, E; Okano, K; Takeo, S. (2001). Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.. Cardiovascular research, 51(3), 608-17.